Abstract
Background: The aim of this study was to explore clinical features and potential mechanisms relating neuropathological biomarkers and blood-brain barrier (BBB) in Alzheimer’s disease (AD) and hearing loss (HL).
Materials and Methods: A total of 65 patients with AD were recruited and auditory function was assessed by threshold of pure tone audiometry (PTA). Patients were divided into AD with HL (AD-HL) and AD with no HL (AD-nHL) groups based on the standard of World Health Organization. Clinical symptoms were assessed by multiple rating scales. The levels of neuropathological biomarkers of β amyloid1-42 (Aβ 1–42) and multiple phosphorylated tau (P-tau), and BBB factors of matrix metalloproteinases (MMPs), receptor of advanced glycation end products, glial fibrillary acidic protein, and low-density lipoprotein receptor related protein 1 were measured.
Results: (1) Compared with AD-nHL group, AD-HL group had significantly impaired overall cognitive function and cognitive domains of memory, language, attention, execution, and activities of daily living (ADL) reflected by the scores of rating scales (P < 0.05). (2) P-tau (S199) level was significantly increased in CSF from AD-HL group (P < 0.05). (3) MMP-3 level was significantly elevated in CSF from AD-HL group (P < 0.05). (4) In AD-HL group, P-tau (S199) level was significantly and positively correlated with the levels of MMP-2 and MMP-3 in CSF (P < 0.05).
Conclusion: AD-HL patients have severely compromised overall cognitive function and ADL. The potential mechanisms involve elevations of P-tau (S199) and BBB factor MMP-3. Findings suggest the significance of early evaluation of HL for delaying AD progression.
Introduction
Hearing loss (HL) is one of the most significant modifiable risk factors for dementia. However, the biological link between sensory deprivation and Alzheimer’s Disease (AD) progression remains a subject of debate. Does hearing loss simply reduce "cognitive reserve," or does it trigger biological changes—like increased protein aggregation or a leakier blood-brain barrier (BBB)—that accelerate the disease? This study seeks to bridge this gap by determining if AD patients with hearing loss have a distinct biomarker profile compared to those with normal hearing.
Methods
The researchers conducted a cross-sectional study of 65 AD patients at Beijing Tiantan Hospital. Auditory function was categorized using Pure Tone Audiometry (PTA). Cognitive status was measured using a comprehensive battery (MMSE, MoCA, AVLT, etc.). Cerebrospinal fluid (CSF) was collected via lumbar puncture to measure neuropathological biomarkers (Aβ1-42, P-tau variants) and BBB integrity factors (MMPs, RAGE, GFAP, LRP1).
Key Results
Cognitive Impact of Hearing Loss
A staggering 67.69% of the AD patients (44 out of 65) had some form of hearing loss. The AD-HL group scored significantly lower across almost all cognitive domains. For instance, the mean MMSE score was 15.36 for the hearing loss group versus 20.24 for the normal hearing group (P < 0.05).
Biomarker Elevation and BBB Disruption
While amyloid-beta levels were similar between groups, P-tau (S199) was significantly higher in the AD-HL group (median 8.19 pg/ml vs. 6.54 pg/ml). This suggests that hearing loss may be more closely linked to the spread of neurofibrillary tangles than to plaque formation.
Additionally, CSF MMP-3 levels were significantly elevated in the AD-HL group and correlated positively with hearing thresholds. MMPs can degrade the tight junctions of the BBB; thus, their elevation suggests that hearing loss is associated with a "leakier" brain, potentially hindering the clearance of metabolic waste.
Discussion and Future Directions
The study identifies a potential "vicious cycle" where sensory deprivation increases neuroinflammation and tau pathology, which in turn damages the BBB, further accelerating neurodegeneration.
While limited by a small, cross-sectional sample from a single center, the findings highlight the importance of early hearing evaluation. Future longitudinal studies are needed to investigate whether interventions like hearing aids can lower CSF P-tau and MMP-3 levels and successfully delay AD progression.
Summary updated